Endologix has reported the 36-month outcomes of a study that evaluated its DETOUR System for treating complex peripheral arterial disease (PAD). The DETOUR 2 Study results were presented at the VIVA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback